Trial · NCT03733444
Adverse events393
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 393
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Weight decreased | Investigations | Placebo | 8 | 258 | 9 |
| other | Weight decreased | Investigations | GLPG1690, 600 mg | 14 | 259 | 16 |
| other | Weight decreased | Investigations | GLPG1690, 200 mg | 9 | 260 | 14 |
| other | Cough | Respiratory, thoracic and mediastinal disorders | Placebo | 22 | 258 | 27 |
| other | Cough | Respiratory, thoracic and mediastinal disorders | GLPG1690, 600 mg | 24 | 259 | 32 |
| other | Cough | Respiratory, thoracic and mediastinal disorders | GLPG1690, 200 mg | 20 | 260 | 23 |
| other | Idiopathic pulmonary fibrosis | Respiratory, thoracic and mediastinal disorders | Placebo | 14 | 258 | 17 |
| other | Idiopathic pulmonary fibrosis | Respiratory, thoracic and mediastinal disorders | GLPG1690, 600 mg | 24 | 259 | 34 |
| other | Idiopathic pulmonary fibrosis | Respiratory, thoracic and mediastinal disorders | GLPG1690, 200 mg | 18 | 260 | 21 |
| other | Dyspnoea | Respiratory, thoracic and mediastinal disorders | Placebo | 22 | 258 | 25 |
| other | Dyspnoea | Respiratory, thoracic and mediastinal disorders | GLPG1690, 600 mg | 14 | 259 | 14 |
| other | Dyspnoea | Respiratory, thoracic and mediastinal disorders | GLPG1690, 200 mg | 12 | 260 | 14 |
| other | Headache | Nervous system disorders | Placebo | 15 | 258 | 16 |
| other | Headache | Nervous system disorders | GLPG1690, 600 mg | 16 | 259 | 19 |
| other | Headache | Nervous system disorders | GLPG1690, 200 mg | 14 | 260 | 17 |
| other | Diarrhoea | Gastrointestinal disorders | Placebo | 47 | 258 | 89 |
| other | Diarrhoea | Gastrointestinal disorders | GLPG1690, 600 mg | 74 | 259 | 199 |
| other | Diarrhoea | Gastrointestinal disorders | GLPG1690, 200 mg | 58 | 260 | 104 |
| other | Nausea | Gastrointestinal disorders | Placebo | 13 | 258 | 14 |
| other | Nausea | Gastrointestinal disorders | GLPG1690, 600 mg | 23 | 259 | 36 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03733444/events